Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (1-10 of 315) with videos related to

Pageof 32
Sort By:
Expert Review of Anticancer Therapy|December 31, 2002
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addictionPaul Workman
Current Pharmaceutical Design|April 8, 2003
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and developmentPaul Workman
Molecular Cancer Therapeutics|February 18, 2003
Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamicsPaul Workman
Cancer Letters|March 12, 2004
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperonePaul Workman
Cancer Discovery|April 13, 2013
Q&A: Paul Workman on big data and large biasesPaul Workman
Advances in Experimental Medicine and Biology|April 17, 2020
Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal PerspectivePaul Workman
Nature|June 13, 2014
Academia and industry: Successes for UK cancer partnershipPaul Workman
Molecular Biosystems|September 5, 2006
Genomics and the second golden era of cancer drug developmentPaul Workman
Future Oncology (London, England)|March 25, 2006
New cancer drugs on the horizonPaul Workman
Current Cancer Drug Targets|October 8, 2003
Overview: translating Hsp90 biology into Hsp90 drugsPaul Workman
Pageof 32

Showing results (1-10 of 315) with videos related to

Sort By:
Pageof 32
Expert Review of Anticancer Therapy|December 31, 2002
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addictionPaul Workman
Current Pharmaceutical Design|April 8, 2003
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and developmentPaul Workman
Molecular Cancer Therapeutics|February 18, 2003
Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamicsPaul Workman
Cancer Letters|March 12, 2004
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperonePaul Workman
Cancer Discovery|April 13, 2013
Q&A: Paul Workman on big data and large biasesPaul Workman
Advances in Experimental Medicine and Biology|April 17, 2020
Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal PerspectivePaul Workman
Nature|June 13, 2014
Academia and industry: Successes for UK cancer partnershipPaul Workman
Molecular Biosystems|September 5, 2006
Genomics and the second golden era of cancer drug developmentPaul Workman
Future Oncology (London, England)|March 25, 2006
New cancer drugs on the horizonPaul Workman
Current Cancer Drug Targets|October 8, 2003
Overview: translating Hsp90 biology into Hsp90 drugsPaul Workman
Pageof 32